Nektar Therapeutics (NKTR) Common Equity (2010 - 2026)

Nektar Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $576.2 million for Q1 2026.

• On a quarterly basis, Common Equity rose 4094.32% year-over-year to $576.2 million in Q1 2026; TTM through Mar 2026 was $576.2 million, a 4094.32% increase from a year earlier, with the FY2025 full-year figure at $89.8 million, up 47.9% from the prior year.
• Common Equity advanced to $576.2 million in Q1 2026 per NKTR's latest filing, from $89.8 million in the prior quarter.
• Across five years, Common Equity topped out at $607.9 million in Q1 2022 and bottomed at -$24.2 million in Q2 2025.
• The 5-year median for Common Equity is $131.0 million (2023), against an average of $213.5 million.
• Across the five-year window, Common Equity plunged 130.38% in 2025 and surged 4094.32% in 2026, its largest moves.
• Year by year, Common Equity stood at $366.6 million in 2022, then tumbled by 64.27% to $131.0 million in 2023, then slumped by 53.63% to $60.7 million in 2024, then jumped by 47.9% to $89.8 million in 2025, then jumped by 541.44% to $576.2 million in 2026.
• Per Business Quant, the three latest NKTR Common Equity figures stand at $576.2 million (Q1 2026), $89.8 million (Q4 2025), and $85.1 million (Q3 2025).